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Zusammenfassung 
Hintergrund 
Weltweit leben mehr als 2,5 Millionen Menschen mit Multipler Sklerose, 
einer progressiven, degenerativen Erkrankung des zentralen Nervensystems 
[1]. In Österreich waren im Jahr 2017 ca. 13.000 Menschen betroffen [2]. 
Multiple Sklerose ist eine der häufigsten neurologischen Erkrankungen bei 
jungen Erwachsenen zwischen 20 und 40 Jahren, wobei die Verteilung nach 
Geschlecht (mehr Frauen als Männer leiden unter der Erkrankung) und ge-
ografische Lage (eine höhere Prävalenz wird in vom Äquator entfernten Re-
gionen beobachtet) variiert. Letzteres ist ein möglicher Hinweis darauf, dass 
eine reduzierte Sonneneinstrahlung in Verbindung mit niedrigen Vitamin-D-
Spiegeln ein Auslöser für die Krankheit sein könnte [3]. Darüber hinaus be-
sitzt MS eine polygene Ätiologie, wobei die stärksten Assoziationen innerhalb 
des Histokompatibilitätskomplexes (MHC) gefunden wurden [4]. 
Die typischen sklerotischen Plaques (Läsionen) resultieren von multiplen 
Entzündungsprozessen, die letztendlich zur Zerstörung des neuronalen Ge-
webes führen. Abhängig vom Ort der Läsionen manifestieren sich klinische 
Symptome, welche motorische Defizite, sensorische Probleme, Sprech- und 
Sehbehinderungen sowie Fehlfunktionen des Urogenitalsystems und kogni-
tive Beeinträchtigungen beinhalten [5, 6]. Darüber hinaus leiden viele Pati-
enten an chronischen neurologischen Schmerzen, welche durch Fehlfunkti-
onen des Nervensystems verursacht werden [7]. 
Die Krankheit kann derzeit nicht endgültig geheilt werden. Verfügbare phar-
makologische Therapien zielen daher darauf ab, den Krankheitsverlauf durch 
Suppression bzw. Modulation des Immunsystems zu verzögern. 
Der monoklonale Antikörper Natalizumab (Tysabri®) wurde 2006 von der 
Food and Drug Administration (FDA) und der European Medicines Agency 
(EMA) zur Behandlung der schubförmig remittierenden Multiplen Sklerose 
zugelassen. Er bindet an das Integrin-Rezeptormolekül VLA-4 (very late an-
tigen-4) und blockiert dadurch die Transmigration von Immunzellen in das 
ZNS. In klinischen Studien hat sich Natalizumab im Vergleich mit Plazebo 
als sehr wirksam erwiesen, jedoch ist die Therapie mit einem erhöhten Risi-
ko für progressiven multifokalen Leukoenzephalopathie (PML) verbunden.  
 
Methoden 
Ziel dieser systematischen Übersichtsarbeit war zu untersuchen, ob Natalizu-
mab über einen Behandlungszeitraum von mindestens 36 Monaten wirk-
samer und sicherer als alternative pharmakologische Therapien (oder Place-
bo) in Bezug auf jährliche Schubrate, Krankheitsverlauf, Lebensqualität und 
Anzahl der schwerwiegenden Nebenwirkungen ist. 
Eine systematische Literaturrecherche wurde in vier Datenbanken durchge-
führt (Medline via Ovid, Embase via Ovid, Toxline und Cochrane Central). 
Dabei wurden ausschließlich prospektive Studien und Publikationen, welche 
seit 2011 (dem Zeitpunkt der Veröffentlichung des Cochrane Reviews) in eng-
lischer Sprache publiziert wurden, eingeschossen. Darüber hinaus wurde im 
Studienregister ClinicalTrials.gov nach laufenden klinischen Studien und Be-
obachtungsstudien gesucht. Insgesamt ergab die Suche nach Deduplikation 
303 Resultate, wovon 35 Studien im Volltext ausgewertet wurden. 7 Publika-
tionen wurden als relevant erachtet und im nachfolgenden Bericht evaluiert. 
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Ergebnisse 
Zur Beurteilung der klinischen Wirksamkeit erfüllten drei Studien die Ein-
schlusskriterien. Eine randomisierte kontrollierte Studie (RCT) und zwei 
nicht-randomisierte kontrollierte Studien. Insgesamt wurden 1.603 Patien-
ten eingeschlossen, wovon 610 für einen Zeitraum von 6 bis 51 Monaten mit 
Natalizumab behandelt wurden. Patienten der entsprechenden Kontrollgrup-
pe erhielten entweder Fingolimod (n = 789), Placebo (n = 47) oder unter-
brachen die Behandlung mit Natalizumab (n = 81). Der RCT wurde vom 
Hersteller Biogen Idec gesponsert. 
Zur Beurteilung der Sicherheit erfüllten sieben Studien die Einschlusskrite-
rien. Die drei o. a. kontrollierten Studien sowie vier einarmige Studien mit 
insgesamt 6335 Patienten. Die Studiendauer der nicht kontrollierten Studien 
lag zwischen 42 und 60 Monaten. Drei Studien wurden vom Hersteller Bio-
gen Idec finanziert. 
Klinische Wirksamkeit 
Im Beobachtungszeitraum von mindestens 36 Monaten wurden keine signi-
fikanten Unterschiede in Bezug auf die jährliche Schubrate und den Krank-
heitsverlauf zwischen Natalizumab und Fingolimod, einer alternativen me-
dikamentösen Therapie, gefunden.  
Im Vergleich mit Plazebo bzw. einer Gruppe von Patienten, welche die Na-
talizumab-Therapie zu unterschiedlichen Zeitpunkten abbrachen, zeigte Na-
talizumab jedoch eine 70 % Reduktion der Schubrate (Ratenverhältnis von 
0,33 bzw. 0,31). Die mittels EDSS bestimmte Veränderung im Krankheits-
verlauf von mit Natalizumab behandelten Patienten betrug -0,22 bis +0,05 
Einheiten. In den entsprechenden Kontrollgruppen lagen die Werte zwischen 
+0,19 und +0,38 Einheiten. 
Eine einzelne Studie (RCT) untersuchte die Lebensqualität der Patienten, wo-
bei jedoch kein signifikanter Unterschied zwischen der Interventions- und 
der Kontrollgruppe beobachtet wurde. 
Sicherheit 
Vier Studien dokumentierten Nebenwirkungen der Therapie, wobei der An-
teil von Patienten mit schweren Nebenwirkungen zwischen 2,4 % und 16 % 
lag. Die am häufigsten genannten waren dabei Infektionen und parasitäre 
Erkrankungen (bis zu 4 %), Neoplasmen (bis zu 2 %) sowie Überempfindlich-
keitsreaktionen (0,5 % bis 2 %). Insgesamt wurden 35 Fälle von PML gemel-
det. 14 Todesfälle traten auf, von denen einer eindeutig PML zugeschrieben 
wurde. 
 
Diskussion und Schlussfolgerung 
Generell wurde die Qualität der Evidenz hinsichtlich der klinischen Wirksam-
keit als niedrig bis sehr niedrig eingestuft. Die Hauptgründe dafür waren 
ein Mangel an RCTs und ein schwerwiegendes Risiko für Bias aufgrund des 
Auswahlverfahrens der TeilnehmerInnen, fehlender Daten sowie Anzeichen 
von selektiven Ergebnisberichten. Die Qualität der kontrollierten Studien 
wurde wegen geringer Stichprobengröße sowie der sehr kurzen Nachbeobach-
tungszeit herabgestuft. 
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Bzgl. der Sicherheit wurde die Qualität der Evidenz aufgrund von Teilberich-
ten, Unklarheiten in Bezug auf die Klassifizierung der Interventionsgruppen 
sowie möglichen Abweichungen von der ursprünglichen vorgesehenen Inter-
vention auf niedrig bis sehr niedrig herabgestuft. 
Nur eine Studie lieferte Daten über die Lebensqualität. Die Meldung schwer-
wiegender Nebenwirkungen war aufgrund unvollständiger Berichterstattung 
und mangelnder Klarheit in Bezug auf die Klassifizierung der Interventions-
gruppen ein wesentlicher Punkt der Beanstandung. 
Die Studien wurden in Europa, Japan und den USA sowie im multinationalen 
Kontext durchgeführt und besitzen dadurch eine externe Gültigkeit. Gleich-
zeitig verhindern Unterschiede zwischen den Ein- und Ausschlusskriterien 
jedoch die Generalisierbarkeit. Daten wurden im Krankenhaus oder von prak-
tizierenden Neurologen und Ärzten aufgezeichnet. Darüber hinaus wurden 
schwangere Frauen, Kinder sowie Patienten mit anderen MS-Formen ausge-
schlossen. 
Aufgrund der spezifischen Anforderungen dieses Berichts (Konzeption als 
Masterthesis), wurden Literatursuche, Auswahl der Publikationen, Datenex-
traktion, Evaluation des Bias-Risikos sowie die Qualität der Evidenz nur von 
einer Wissenschaftlerin durchgeführt. Daher konnten standardisierte Quali-
tätssicherungsprozesse (z. B. die Auswahl von Studien durch zwei unabhän-
gige Gutachter) nicht angewendet werden. 
Fazit 
Die aktuelle Evidenz deutet darauf hin, dass Natalizumab im Vergleich mit 
Fingolimod keine signifikanten Unterschiede in Bezug auf die jährliche 
Schubrate und den Krankheitsverlauf über einen Beobachtungszeitraum von 
mindestens 36 Monaten aufweist. Die Qualität der zugrundeliegenden Evi-
denz ist jedoch als niedrig bis sehr niedrig einzustufen. In Bezug auf die Si-
cherheit wurden keine Daten im Vergleich mit alternativen Behandlungs-
methoden gefunden. 
Der Fokus zukünftiger klinischer Forschung sollte daher in direkten Ver-
gleich von Natalizumab mit anderen krankheitsmodulierenden Medikamen-
ten (z. B. Interferon-beta, Fingolimod) liegen. Zusätzlich sollten Nebenwir-
kungen vollständig und umfassendener dokumentiert werden. 
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Summary 
Introduction 
Worldwide, more than 2.5 million people suffer from Multiple Sclerosis (MS), 
which is a progressive, degenerating disease of the Central nervous system 
(CNS) [1]. In Austria, approximately 13,000 individuals were affected in 2017, 
resulting in a prevalence ratio of 159 per 100,000 person-years [2].  
Multiple sclerosis is one of the most frequent neurological conditions among 
young adults, although younger as well as older people can be affected [4]. 
The distribution varies according to sex (more women than men suffer from 
the condition) and the geographic location. A higher prevalence is observed 
in regions that are situated away from the equator indicating that reduced 
sunlight exposure in connection with low levels of vitamin D might be a trig-
ger for the disease [3]. Moreover, MS possesses a polygenic etiology, whereby 
the strongest association has been found within the major histocompatibility 
complex (MHC) [4].  
The typical sclerotic plaques (lesions) within the CNS originate from multi-
ple inflammation processes which ultimately destroy the neuronal tissue. The 
clinical manifestations are heterogeneous and depend on the location of the 
lesions. They include motor deficits, sensory problems, speech and vision 
impairments and malfunctions of the urogenital system and cognitive im-
pairments [5, 6]. Furthermore, the majority of the patients suffer from chron-
ic neuropathic pain caused by the dysfunction of the nervous system [7]. 
Description of the intervention 
Currently, there is no definitive cure. Therefore, available pharmacological 
therapies aim to reduce the disease activity either by suppressing or by mod-
ulating the immune system.  
The humanized monoclonal antibody natalizumab (Tysabri®) was approved 
for the treatment of relapsing-remitting multiple sclerosis by the Food and 
Drug Administration (FDA) and the European Medicines Agency (EMA) in 
2006. It binds to the integrin receptor molecule VLA-4 (very late antigen-4) 
and thereby efficiently blocks the transmigration of immune cells into the 
CNS. In placebo-controlled randomised trials, natalizumab has been shown 
to be highly effective [8]. However, the therapy has been associated with an 
increased risk of developing progressive multifocal encephalopathy (PML) 
which is a severe opportunistic infection of the brain. Therefore, patients re-
ceiving natalizumab therapy have to be monitored regularly. 
 
Methods 
The aim of the systematic review was to investigate whether natalizumab is 
more effective and safer than alternative pharmacological therapies or place-
bo over a long term treatment period (≥ 36 months) with respect to annual-
ized relapse rate, disability progression, QoL and number of serious adverse 
events (SAEs).  
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A systematic literature search was conducted in the following four databases 
(Medline via Ovid, Embase via Ovid, Toxline and Cochrane Central). The 
search was limited to prospective studies, articles published since 2011 (the 
publication of the Cochrane Review analysing natalizumab treatment for re-
lapsing remitting multiple sclerosis) and in English language. After dedupli-
cation, 303 citations were included. Furthermore, the clinical trial registry 
ClinicalTrials.gov was assessed for ongoing clinical trials and observational 
studies. In total, the search yielded 35 results, which were assessed in full-
text, of which 7 were considered relevant. 
 
Results 
Available evidence 
For the assessment of clinical effectiveness, three studies met the inclusion 
criteria. One randomised controlled trial (RCT) and two non-randomised con-
trolled studies. In total, 1,603 patients were included. Out of these, 610 were 
treated with natalizumab for a period between 6 and 51 months. Patients of 
the corresponding control group received either fingolimod (n=789), placebo 
(n=47) or did interrupt natalizumab treatment (n=81). The RCT was spon-
sored by the manufacturer Biogen Idec.  
For the assessment of safety, seven studies met the inclusion criteria. The 
three controlled trials above, and four single-arm studies with a total of 6,335 
patients. The follow-up periods lasted between 42 to 60 months. Three stud-
ies were funded by Biogen Idec. 
Clinical effectiveness 
No significant differences regarding the annualized relapse rate and disa-
bility progression were found, if natalizumab was compared to fingolimod 
therapy (rate ratio of 0.93 (95% CI. 0.74-1.17), p=0.53).  
However, compared to either a placebo control or a group of patients inter-
rupting natalizumab therapy, natalizumab showed an approx. 70% reduction 
in the annualized relapse rate (rate ratio of 0.33 and 0.31, respectively). The 
change in EDSS scores ranged from -0.22 to +0.05 units in natalizumab treat-
ed patients compared to a difference of +0.19 to +0.38 units in the respec-
tive control groups.  
Concerning QoL, only one trial (RCT) investigated this patient-reported out-
come. Yet, no significant difference was observed between the intervention 
and the control group.  
Safety 
Four studies reported adverse events. The proportion of patients suffering 
from SAEs ranged from 2.4% to 16%. The most frequent were infections and 
infestations (up to 4%), neoplasms (up to 2%) and hypersensitivity reactions 
(0.5% to 2%). In total, 35 cases of PML were reported. 14 deaths occurred, 
one of which was attributed unambiguously to PML. 
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Discussion and conclusion 
Concerning clinical effectiveness, the quality of evidence was low to very low. 
The main reasons were lack of RCTs and serious risk of bias due to selection 
of participants, missing data and selective outcome reporting. Studies com-
paring patients receiving natalizumab with either those who interrupt the 
treatment or with a placebo control were downgraded due to small sample 
size, short follow-up period and bias in the selection of the participants. 
Concerning safety, the quality of evidence was low to very low due to partial 
reporting, lack of clarity regarding the classification of the intervention groups 
and potential deviation from the intended interventions. 
In terms of outcomes, data about the quality of life was lacking in all but one 
study. The reporting of serious adverse events was a major point of concern 
due to partial reporting and lack of clarity regarding the classification of the 
intervention groups.  
In terms of extern validity, the data is considered generalizable to other con-
texts. The studies were conducted in Europe, Japan and the USA and in mul-
tinational settings. Yet, differences between inclusion and exclusion criteria 
prevent the generalizability. Data were recorded in hospital settings or by 
practising neurologists and physicians. Furthermore, pregnant women, chil-
dren, or patients with other forms of MS were excluded. 
Due to the specific requirements of this report, only one researcher performed 
the literature search, the selection of eligible publications and the data-ex-
traction in addition to assessing the risk of bias and evaluating the quality of 
evidence for each outcome. Hence, standard quality assurance processes (e.g. 
selection of studies by two reviewers independently) could not be applied.  
Conclusion 
The current evidence indicates that there are no significant differences be-
tween natalizumab and fingolimod in terms of ARR and disability progres-
sion over a prolonged treatment period (≥36 months). However, the quality 
of the body of evidence suggesting this is low to very low. In terms of safety, 
no evidence was found, whether natalizumab therapy is safer than any treat-
ment alternatives.  
Thus, future research should provide more head-to-head RCTs comparing 
natalizumab with other disease modulating drugs (e.g. interferon beta, fin-
golimod) along with a comprehensive documentation of adverse events. 
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1 Introduction 
1.1 Description of the condition 
Multiple Sclerosis (MS) is an autoimmune disease of the central nervous sys-
tem (CNS) which affects more than 2.5 million people worldwide [1]. In Aus-
tria, approximately 13,200 individuals were affected in 2017 with an incidence 
rate of 19.5 per 100,000 person-years (95% CI 14.3-24.7) and a prevalence ra-
tio of 158.9 per 100,000 person-years (95% CI 141.2-175.9), respectively [2].  
MS is commonly diagnosed between 20 and 40 years of age, although young-
er as well older people can be affected [4]. The distribution varies according 
to sex as twice as much women than men suffer from the condition and the 
geographic location. A higher prevalence is observed in regions that are situ-
ated away from the equator indicating that reduced sunlight exposure in con-
nection with low levels of vitamin D might be a trigger for the disease [3]. 
Additionally, MS possesses a genetic component as an increased risk is ob-
served within families or in certain ethnic communities. The strongest asso-
ciation has been found within the major histocompatibility complex (MHC), 
which is a highly variant region within the human genome. Yet, recent ge-
nome wide association studies (GWAS) identified more than 110 non-MHC 
risk variants, suggesting a polygenic etiology [4]. 
The pathophysiological mechanism involves autoreactive T-cells that cause 
the myelin sheath damage. These are supported by B-lymphocytes which pro-
duce pro-inflammatory cytokines, thereby attracting further immune cells. 
Ultimately, the inflammation process destroys the neuronal tissue and leads 
to the formation of sclerotic plaques (lesions) [1]. 
The diagnosis is usually based on medical history and physical examination, 
which are formalized as the McDonald criteria [9]. These include imaging 
techniques like magnetic resonance imaging (MRI) for the identification of 
white matter lesions as well as specific laboratory tests [10]. 
About 85% of MS patients develop a relapsing-remitting multiple sclerosis 
(RRMS) in which the characteristic inflammatory events alternate with phas-
es of partial or even full recovery [4]. This phase could last from years to even 
decades. Finally, however, the disease progresses into a secondary progres-
sive form (SPMS), in which the neurological disabilities due to axonal injury 
and neuronal loss become irreversible [4]. Approximately 15% of the patients 
experience a more severe disease pattern called primary progressive multi-
ple sclerosis (PPMS). These individuals are immediately affected by irrever-
sible neurodegeneration events [4]. 
The clinical manifestations are heterogeneous and depend on the location of 
the lesions. They could comprise a variety of symptoms including motor def-
icits, sensory problems, speech and vision impairments and malfunctions of 
the urogenital system [5]. Furthermore, the majority of the patients suffer 
from chronic neuropathic pain that is caused by the dysfunction of the nerv-
ous system [7]. 
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Pharmacological therapies 
Currently, there is no definitive cure. Thus, the main aim of the therapy is 
to reduce the disease activity and thereby delay the degenerative progression 
either by suppressing or by modulating the immune system [5]. Furthermore, 
it has been shown that any delay in treatment is associated with a greater 
risk of reaching score 4 (fully ambulatory, up about 12 hours a day despite 
relatively severe disability) on the Enhanced Disability Status Scale (EDSS) 
sooner. In contrast, earlier treatment results in fewer hospitalization events, 
a reduction of relapses and a gain of quality adjusted life years (QALYs) [5]. 
During acute relapses, immunosuppressants (primarily corticosteroids) are 
used to alleviate of some symptoms and to reduce the duration of the relaps-
es. In exceptional cases, a plasmapheresis is performed [8, 11]. Additionally, 
disease-modifying therapies have been developed, which are able to reduce 
the rate of relapses as well as the occurrence of MRI lesions by altering the 
immune system. Furthermore, they have been shown to stabilize or delay MS 
associated disabilities [1]. Initially, so-called first-line treatments (e.g. Inter-
feron-beta or Glatiamer acetate) are used which exhibit a moderate efficacy 
together with high safety profile. Usually they induce nonspecific changes 
within the immune system. In case of an unsatisfactory response to first line 
drugs or in patients with highly active disease, second-line treatments (for 
instance, monoclonal antibodies like natalizumab or ocrelizumab, or the 
sphingosine analogue fingolimod) are available. These are more effective, but 
are also accompanied with increased safety issues [1, 5, 12].  
Although current treatments are able to decrease the relapse rate in RRMS, 
most of the patients experience a worsening of the neurological functions dur-
ing the course of the disease, albeit it is slow in most patients. A large longi-
tudinal study with 2,319 patients evaluating 22,723 patient-years, showed that 
the median time from disease onset to EDSS 6 (unilateral assistance neces-
sary for ambulation) was 27.9 years [13]. The disease has a major impact on 
the employment status of the patients as fatigue and cognitive difficulties re-
duce the people’s productivity. A study showed that 18% of patients with a 
mild disease are unemployed compared to a 92% unemployment rate of peo-
ple suffering from a more severe disease [5, 14].  
The overall costs of the disease rise with increasing severity. The estimated 
average costs per year range from 22,800 euros (mild disease) to 57,500 euros 
(severe disease) [5]. During the early stages they are mainly caused by the 
pharmacological treatment. Later, however, they increase due to the limita-
tions at work, increased hospitalization, the requirements for accessing re-
habilitation centres or the needs for assistance during relapse and recovery 
[5]. 
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1.2 Description of the intervention 
The humanized monoclonal antibody natalizumab (Tysabri®) was approved 
by the Food and Drug Administration (FDA) for the treatment of relapsing-
remitting multiple sclerosis after a priority review from two ongoing trials 
(SENTINEL and AFFIRM) in 2004. Yet, after two cases of progressive mul-
tifocal leukoencephalopathy (PML), which is an uncommon and severe op-
portunistic brain infection, Biogen Idec and its former associated partner 
Elan Pharmaceuticals suspended both, commercialisation and clinical trials 
in 2005. After a comprehensive investigation and submission of the 2-year 
results of SENTINEL and AFFIRM, the drug was reintroduced in July 2006 
[8]. Natalizumab was authorized in the European Union in June 2006 and is 
indicated as single disease modifying therapy in adults with highly active re-
lapsing remitting multiple sclerosis either as second-line treatment or in treat-
ment naïve patients with rapidly evolving severe relapsing remitting multi-
ple sclerosis [15].  
 
How the intervention might work 
Natalizumab binds to the integrin molecule VLA-4 (very late antigen-4), 
which is expressed on the surface of T cells, B cells, monocytes, macrophages, 
natural killer cells, dentritic cells, neutrophils and eosinophils. In turn, these 
cells are unable to attach to VCAM-1 (vascular cell adhesion molecule 1) that 
is located on the endothelial cells of the blood vessels. Thereby, natalizumab 
effectively blocks the migration of the immune cells into the CNS [12, 16, 17]. 
The efficacy and safety of natalizumab was previously evaluated in a sys-
tematic review published in 2011 by Pucci and colleagues [8]. It was based 
on three randomised controlled trials (AFFIRM 2006, SENTINEL 2006 and 
GLANCE 2009). The authors found significant evidence in favour of natali-
zumab therapy, as patients of the intervention group exhibited a reduced the 
risk of experiencing at least one new exacerbation after 2 years by 30% to 50% 
and of experiencing progression at 2 years by 10% to 40%, if compared to ei-
ther those receiving interferon-beta or a placebo control group [8]. In terms 
of QoL, the comparison of the mean difference in the SF-36 scale (Short form 
(36) health survey) between intervention and control group favoured natali-
zumab treated patients. Regarding safety, the analysis showed that the num-
ber of patients experiencing at least one severe AE did not differ between 
groups. Furthermore, the frequency of serious AE (including MS relapses) 
was less common in the natalizumab treated group than in the control group 
(18% versus 21%) [8]. In summary, natalizumab was well tolerated, although 
the protocol was insufficient to evaluate the risk of progressive multifocal 
leukoencephalopathy [18]. 
The relative benefit and acceptability of current therapies for the treatment 
of people with RRMS was determined by two further systematic reviews us-
ing network meta-analyses to compare multiple treatments [19, 20]. Trama-
cere and coworkers analysed 39 studies with a median duration of two years, 
yet only one trial investigating natalizumab therapy (AFFIRM 2006) was in-
cluded. The other review published by the group of Filippini combined the 
results of two natalizumab RCTs (AFFIRM 2006 and SENTINEL 2006) in a 
group of 44 trials that were analysed. Natalizumab was considered either as 
third most effective drug [19] or (along with INFß-1a) as superior to all oth-
er treatments in preventing clinical relapses in RRMS compared to the pla-
cebo group for a duration of two years [20]. 
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The rationale of this review is to compare the efficacy and safety of natali-
zumab with alternative immunomodulating therapies or placebo. The treat-
ment effect of natalizumab will be calculated by including randomized and 
non-randomized controlled trials that have been undertaken since the publi-
cation of the first systematic. Potential long-term effects will be evaluated by 
including observational studies. 
 
 
1.3 Research objectives 
1. To estimate the effect of the treatment with the monoclonal antibody na-
talizumab by analysing the number of relapses (Annualized Relapse Rate – 
ARR) and the proportion of participants who experienced disability wors-
ening (Enhanced Disability Status Score – EDSS) over specified time pe-
riods depending on the length of the studies under investigation. 
2. To investigate whether the patient-reported quality of life (QoL) outcome 
is related to the disability status of the participants. 
3. To determine the safety of natalizumab either applied as a first line treat-
ment or as secondary regimen by determining the number of serious ad-
verse events. 
 
 
1.4 Research question 
Is the treatment with natalizumab effective and safe for patients with relaps-
ing-remitting multiple sclerosis in comparison to alternative therapies (or 
placebo)? 
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2 Methods 
2.1 Criteria for considering studies 
for this review 
The inclusion criteria for relevant studies are summarized in Table 2.1-1. 
Table 2.1-1: Inclusion criteria 
Population Adult patients (18-65 years) with a diagnosis of  
Relapsing-remitting Multiple Sclerosis according to the accepted diagnostic criteria. 
Intervention Natalizumab, 300 mg, IV, every 28 days 
Control Alternative therapy or placebo 
Outcomes (crucial) Efficacy/Effectiveness 
 Number of relapses (Annualized Relapse Rate – ARR) 
 Disability worsening (Enhanced Disability Status Score – EDSS) 
 QoL 
Safety 
 Number of Serious adverse events (SAEs) 
Study design Efficacy/Effectiveness 
 Randomised controlled studies (RCTs) 
 Prospective (non-randomised) controlled trials with a minimum treatment period  
of 36 months 
Safety 
 Randomised controlled studies (RCTs) 
 Prospective (non-randomised) controlled trials with a minimum treatment period 
of 36 months 
 Prospective single-arm studies with a minimum treatment period of 36 months 
Publication period 2011-2018 
Language English 
 
Types of participants 
For this review, adult patients (18-65 years) with a diagnosis of RRMS (ac-
cording to the accepted McDonald criteria) regardless of age, sex, severity of 
disease or treatment duration were included. However, persons with Clinical 
isolated syndrome (CIS) were excluded as not all people who are diagnosed 
with CIS later develop MS [21]. 
 
Type of intervention 
The effect of standard natalizumab treatment (300mg, IV, every 28 days) was 
compared to other immunomodulating therapies irrespective of their dosing 
regimen. Alternatively, a placebo control was considered, if no other therapy 
was used. 
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Types of outcome measures 
The following outcomes were considered as critical. 
1. Annualized relapse rate (ARR). A relapse is defined as new or recur-
rent neurological symptoms that is not associated with fever or other 
acute diseases and which lasts for more than 24 hours and is followed 
by a period of at least 30 days of stability or improvement [9]. 
2. Disability progression measured by the Expanded Disability Status 
Scale (EDSS). EDSS is a common measure for MS disability with a 
score from 0 to 10 in half point increments on an ordinal scale, where 
‘0’ represents ‘normal’ and ‘10’ is death from MS. Progression is de-
fined as the difference between the baseline EDSS score and the EDSS 
score measured at different time-points during follow-up. A clinically 
meaningful change is generally considered as a persistent worsening 
of at least 1.0 in EDSS that is recorded outside a relapse and confirmed 
by a follow-up assessment, if the baseline EDSS score ranged between 
0 and 5.5 or a 0.5 point increase, if the baseline EDSS was greater than 
5.5 [22]. 
3. Quality of Life (QoL). Any test which measures the patient-reported 
outcome quality of life would be accepted. 
4. The number of serious adverse events (SAEs). If available, data about 
the number of infections and neoplasms will be collected. Due to the 
treatment, the immune system of the patients is altered, which might 
favour the formation of these conditions. Additionally, the number of 
PML cases would be of interest as this severe opportunistic infection 
is a known to be associated with natalizumab treatment. 
In terms of safety, the number of adverse events will be considered as further 
outcome. Data about hypersensitivity reactions and the proportion of partic-
ipants with antibodies against JCV or natalizumab will be reported.  
 
Types of studies 
For evaluating effectiveness, RCTs which studied natalizumab therapy for 
the treatment of RRMS patients were included. Due to their high metholog-
ical quality, RCTs independently of the length of their respective follow-up 
period were included. As comparator, any alternative therapies or – in case 
no other therapies were applied – a placebo control was considered. Prospec-
tive, non-randomized controlled trials with a minimum treatment period of 
36 months were included in order to evaluate the effectiveness of natalizu-
mab over this prolonged treatment period. In contrast, retrospective studies 
and those with a follow-up of less than 36 were excluded.  
In terms of safety, prospective single-arm studies with a minimum treatment 
period of 36 months or more were additionally included in order to be able 
to assess long-term adverse events. Retrospective studies as well as case series 
or case reports were excluded. 
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2.2 Search methods for identification 
of studies 
The systematic literature search was conducted in the following four data-
bases: Embase (via Ovid), Medline (via Ovid), Cochrane CENTRAL and Tox-
line. The search was limited to articles written in English and those published 
from 2011 onwards. The specific search strategy can be found in the appen-
dix. Registered clinical trials were identified by searching the ClinicalTri-
als.gov registry. 
 
 
2.3 Data collection and analysis 
The data from the selected studies were systematically extracted into the data-
extraction tables (see appendix, Table 8.1-3). From each included study, data 
on the study characteristics (country of origin, sponsor and duration period 
as well as the design, number of patients, inclusion and exclusion criteria) 
was recorded. The baseline patient characteristics included data on age, sex, 
time since MS diagnosis, prior MS therapy, number of relapses in previous 
year and mean number of EDSS score at baseline. Outcome data was retrieved 
upon the annualized relapse rate and the disability progression measured by 
the Expanded Disability Status Scale. In addition, data about patient-report-
ed quality of life was collected. Furthermore, the number of serious adverse 
events and adverse events was extracted from the studies. Besides, informa-
tion about the duration of the follow-up, the number of those lost to follow-
up as well as details of the intervention itself (dose, frequency) was recorded. 
No further data processing was applied. 
 
 
2.4 Assessment of risk of bias  
in included studies 
The risk of bias in randomized controlled trials was assessed using the re-
vised Cochrane risk of bias tool for individually randomized trials (RoB 2.0) 
[23]. For every study outcome, five domains (bias arising due to the random-
ization process, deviations from the intended intervention, missing outcome 
data, measurement error or selection of the reported result) were assessed by 
answering provided signalling questions corresponding to each domain. To 
summarize the quality of evidence as ‘low’ risk of bias, every outcome domain 
has to be judged as low risk. If any domain would be assessed as either ‘some 
concerns’ or high’ risk of bias, the whole study would be classified accordingly. 
For assessing the risk of bias in non-randomized controlled trials, the risk of 
bias in non-randomized studies of interventions (ROBINS-I) was applied 
which compares the effects of two or more interventions [24]. Basically, it 
covers seven domains: two of which are addressed before the start of the in-
tervention (bias due to confounding and in the selection of participants into 
the study), the third classifies the intervention itself (bias in the classification 
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of the interventions), while the other four consider issues after the start of the 
intervention (bias due to deviations from intended interventions, missing da-
ta, measurement of outcomes and selection of the reported result). Again, sig-
nalling questions are used for the domain-level judgement as either ‘low’, 
‘moderate’, ‘serious’, ‘critical’ risk of bias. A ‘no information’ option can be 
used in cases where the text of the publication does not provide any details 
for an appropriate answer. Downgrading the risk of bias in an individual 
domain automatically results in downgrading the overall risk of bias of the 
respective study. 
For observational, single-arm studies, the IHE-20 Quality appraisal check-
list for case series studies was applied [25]. It consists of 20 questions that 
address 8 topics (study objective, design, population, intervention, outcome 
measures, statistical analysis, results and conclusions as well as completing 
interests and sources of support). The questions relating to each topic can be 
answered with either ‘yes’, ‘no’ or ‘partial’/’unclear’ and serve as guidance to 
assess the quality of the study in general. 
 
 
2.5 Data synthesis 
Based on the evidence and the risk of bias tables, data on each selected out-
come category was assessed across studies and evaluated using the GRADE 
approach (Grading of Recommendations, Assessment, Development and Eval-
uation) [26]. Additionally, the main results were presented in a Summary of 
findings (SoF) table (Table 4-1). Finally, the research question was answered 
in plain text format with reference to the GRADE evidence table (Table 4-1). 
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3 Results 
Results of the search (Flow chart) 
After removing duplicates, 303 records were retrieved by the systematic search 
strategy. 35 articles were considered as potentially eligible after screening the 
titles and abstracts of the publications. The evaluation of the corresponding 
full-text resulted in the inclusion of 7 studies for the qualitative synthesis. 
 
Figure 3-1: Flow chart of the study selection. 
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3.1 Efficacy/Effectiveness 
Included studies 
For investigating the efficacy and effectiveness, respectively, three studies met 
the inclusion criteria: one randomised controlled study [27] and two non-ran-
domised controlled trials [28, 29]. 
The studies were performed in Japan [27], Italy [28] and Denmark [29] and 
included 1,603 patients with a mean age of 35.1 to 39.5 years. Approximately 
70% of the participants were female with a mean number of relapses between 
1.05 and 2.29 in the year prior to study enrolment. Out of these patient group, 
610 received natalizumab treatment for a follow-up period between 6 months 
to 51 months. Patients of the corresponding control groups received either 
fingolimod (n=789) [29], placebo (n=47) [27] or did interrupt natalizumab 
treatment followed by one of three options ((1) switching to another disease-
modifying therapy, (2) discontinuing all treatment or (3) beginning intrave-
nous mitoxantrone hydrochloride) (n=81) [28]. The randomised controlled 
trial was sponsored by the manufacturer Biogen Idec. Table 3.1-1 summarizes 
the main characteristics of the studies. 
Table 3.1-1: Overview of the main study characteristics 
Study Saida et al.[27] Clerico et al.[28] Koch-Henriksen et al.[29] 
Design RCT Non-randomised 
controlled trial 
Non-randomised 
controlled trial 
No of patients 94 130 1379 
Lenght of follow-up (months) 6 12 51 
Conflict of interest sponsored by Biogen none none 
 
The RCT included 94 patients, of which 47 were in the intervention group 
(IG) and 47 in the control group (CG) [27]. Patients were excluded if they had 
received prior treatment with natalizumab, immunosuppressants or a positive 
test result for Aquaporin4 antibodies. During the 6 months study period, 5 
patients (5.3%) were lost to follow-up. 
The non-randomized studies included in total 1,509 patients. Clerico et al. 
[28] included 130 patients, of which 6 patients (4.6%) were lost to follow-up. 
Of the remaining 124 patients 43 patients received natalizumab therapy for 
a further period of 12 months, while 81 patients were included in the control 
group. In the non-randomised trial performed by Koch-Henriksen et al. [29], 
the outcomes of natalizumab treatment were compared with fingolimod ther-
apy. Of 1,379 participants, 70 patients (5.1%) were lost during follow-up. Af-
ter propensity score matching, the data of 928 individuals were used for the 
analysis (IG n=464). 
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In terms of differences between inclusion and exclusion criteria between the 
two non-randomised trial, Clerico et al. [28] included patients which under 
natalizumab therapy had a clinical and MRI imaging MS stability as defined 
by the absence of documented relapses and the absence of EDSS progression 
during the preceding 6 months. Further exclusion criteria were pregnancy, se-
vere depression, known alcohol and drug addiction and any clinical condition 
in addition to MS. In contrast, Koch-Henriksen et al. [29] included RRMS 
patients which under first-line treatment with interferon-beta or glatiramer 
acetate experienced at least one significant relapse in the year prior to enrol-
ment. Furthermore, treatment-naïve patients were included, if they suffered 
within a year from two serious relapses with residual symptoms and an active 
magnetic resonance imaging scan with gadolinium positive lesion(s) or a sig-
nificant increase in T2 lesions compared to earlier MRI scans. The exclusion 
criteria were not further specified. 
 
Effect of the intervention 
Annual relapse rate 
The annual relapse rate was investigated in three studies [27-29]. In the study 
which directly compared natalizumab with fingolimod, the crude ARRs af-
ter treatment were 0.30 (95% CI 0.26-0.34) and 0.31 (95% CI 0.27-0.35), re-
spectively. The corresponding adjusted rate ratio was 0.93 (95% CI: 0.74-1.17) 
with a p-value of 0.53, indicating no difference between the two therapies [29]. 
In the two further studies, the ARRs of natalizumab treated patients were 0.24 
(SD0.48) [28] and 0.53 (95% CI: 0.29-0.99) [27], respectively. The correspond-
ing values of the comparator groups ranged from 0.73 (SD 0.85) to 1.73 (95% 
CI: 1.22-2.45). Thus, a significant difference was observed, if patients of the 
intervention group were compared to either a group of natalizumab interrupt-
ers [28] or a placebo control [27]. 
Disability progression 
Data about the disability progression were available from all included stud-
ies [27-29]. Yet, only the RCT [27] and one non-randomised controlled study 
[28] indicated absolute differences.  
No significant difference (p-value 0.86) was observed between natalizumab 
and fingolimod treated patients [29]. In the intervention group 40.1% im-
proved, 31.0% remained unchanged and 28.9% worsened, when comparing 
the EDSS score at the end of the follow-up to the baseline score. Similarly, 
39.9% of the fingolimod-treated patient improved, 32.5% remained un-
changed and 27.6% worsened [29]. 
Data from the other two studies showed that the disability of natalizumab 
treated patients either improved (the mean EDSS score differed by -0.22 ar-
bitrary units (from baseline 2.5 to 2.3, [27]) or remained constant (absolute 
change in EDSS score of 0.05 arbitrary units (from baseline 3.31 to 3.36) [28]). 
In both control groups, however, the disability progressed either by +0.19 
arbitrary units (from baseline 2.1 to 2.3) [27] or by +0.38 arbitrary units (from 
baseline 3.42 to 3.80) [28]. 
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QoL 
The patient-reported outcome QoL was investigated only in the RCT using a 
visual analogue scale (VAS) ranging from 0 to 100, where 0 was considered 
“poor” and 100 “excellent”. The calculated mean change over time was a -4.8 
point reduction in the natalizumab group versus a -2.9 point reduction in the 
control group with a corresponding p-value of 0.942, indicating no significant 
difference between the two groups [27]. 
 
 
3.2 Safety 
Included studies 
In terms of safety, seven studies met the inclusion criteria. Besides the stud-
ies described in the section of clinical efficacy and effectiveness, further four 
observational, single-arm studies were included which will be described be-
low. In total, the data of 12,270 patients were analysed (1603 in the con-
trolled, 6335 in the single-arm studies), of which 7,168 received natalizumab 
therapy.  
The interim analyses from two multinational studies, the Tysabri observation-
al program (TOP) study [30] and the Safety of Tysabri re-dosing and treat-
ment (STRATA) study [31], were included. In addition, one study from Italy 
[32] and one from the USA [33] met the inclusion criteria. The single-arm 
studies included patients from 35.8 to 41.3 years of age, with a female per-
centage between 69.1% and 74.4%. The follow-up periods lasted between 42 
months [32] to 60 months [30, 31, 33]. Three studies were funded by Biogen 
Idec [30, 31, 33]; no sponsor related information was available from the fourth 
study. 
Differences in between studies were found regarding the inclusion criteria. 
In two studies patients were recruited, if they had already been part of an-
other trial investigating natalizumab therapy. Zivadinov and colleagues eval-
uated participants from the voxel-wise magnetization transfer ratio (VWMTR) 
[34] study five years later in order to investigate potential long-term effects 
of natalizumab therapy. In contrast to other studies, RRMS as well as second-
ary progressive MS patients were included [33]. Participants of the STRATA 
study initially received natalizumab therapy in a randomised controlled feed-
er-study. Yet, due to the withdrawal of the drug due to cases of PML in 2005, 
the participants experienced a treatment gap. To investigate the effect of this 
treatment interruption, eligible and willing patients were enrolled in the 
STRATA study [31]. 
Butzkueven and colleagues included RRMS patients who met the criteria for 
natalizumab prescription in their respective countries and had three or fewer 
natalizumab infusions before enrolment. Female participants were supposed 
to be postmenopausal, surgically sterile, or willing to practice effective con-
traception [30]. Totaro and co-authors included patients who were on im-
munomodulatory treatment for at least 12 months and who had experienced 
either two relapses in the last year or a single relapse with incomplete recov-
ery and residual disability. In addition, patients with severe and fast evolving 
MS (defined as 2 or more relapses with increased disability during the pre-
vious year) were recruited, even if they have not previously been treated with 
immunomodulatory treatments [32]. 
RCT: Kein signifikanter 
Unterschied in der 
Lebensqualität 
7 eingeschlossene 
Studien mit  
12.270 PatientInnen, 
davon erhielten  
7.168 Natalizumab 
4 nicht kontrollierte 
Studien, ~70% Frauen, 
FU 42-60 Monate,  
3 Studien finanziert  
von Biogen 
unterschiedliche 
Einschlusskriterien 
 
PatientInnen zweier 
Studien waren bereits 
TeilnehmerInnen von 
klinischen Studien 
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Serious adverse events 
Four studies reported serious adverse events [27, 28, 30, 31]. The proportion 
of of natalizumab treated patients suffering from SAEs ranged from 2.4% [28] 
to 16% [31]. The most common ones were infections and infestations (up to 
4%), neoplasms (up to 2%) and hypersensitivity reactions (0.5% to 2%). On-
ly two studies documented SAEs in the respective control groups: either 1.2% 
(1/81) [28] or 23% (11/47) [27] of the patients suffered from serious adverse 
events. In total, 35 cases of PML were reported [28, 30, 31, 33] and 14 deaths 
occurred [30, 31, 33], one of which was attributed to PML [33]. 
 
Adverse events 
The number of adverse events was documented in three studies [27, 30, 32]. 
Overall, 2.2% [30] to 72% [27] of patients treated with natalizumab reported 
AEs, among which headaches and infections were reported most frequently. 
Hypersensitivity reactions were reported in 3.5% [32] to 5.0% [31] of the par-
ticipants, while 0.9% [30] to 2.1% [27] of the patients developed antibodies 
against natalizumab. 43% [33] to 67% [31] of the patients were tested sero-
positive for JCV. 
 
 
 
 
4 Studien 
dokumentierten 
schwere 
Nebenwirkungen 
 
2.4%-16% der 
PatientInnen 
(insg. 35 Fälle von PML 
und 14 Todesfälle) 
3 Studien 
dokumentieren 
Nebenwirkungen 
2.2%-72% der 
PatientInnen 
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4 Grading of evidence 
Risk of bias in included studies 
The individual studies were assessed with the revised Cochrane risk of bias 
tool for individually randomized trials (RoB 2.0) [23], the risk of bias in non-
randomized studies of interventions (ROBINS-I) [24] and the Institute of 
Health Economics (IHE)-20 checklist for single-arm studies [25]. The assess-
ments are presented in the Table 8.2-1–Table 8.2-3 in the Appendix.  
The randomized controlled trial (REF) was considered as having a low risk 
of bias (RoB) in all domains analysed. However, a conflict of interest was 
present as the study was funded by the manufacturer. Both non-randomised 
controlled studies were considered as having a serious RoB. The study by 
Clerico [28] was downgraded due to high RoB in the selection of the partici-
pants and the classification of the intervention groups as well as due to the 
possibility of deviating from the intended interventions. The reasons for 
downgrading the study performed by Koch-Henriksen [29] were bias due to 
missing data and possible selection of the reported results.  
The overall risk of bias in the single-arm studies varied from moderate [30, 
31, 33] to high [32]. The major factors contributing to a risk of bias were non-
consecutive selection of patients, partial description of the eligibility criteria, 
lack of blinding, lack of documentation of potential losses to follow-up and lack 
of clarity concerning the reporting of co-interventions. A conflict of interest 
was present in three of four studies as they were funded by the manufacturer.  
 
GRADE 
The strength of evidence was rated according to GRADE (Grading of Rec-
ommendations Assessment, Development and Evaluation) schema [26] for 
each endpoint individually. Basically, Grade uses four categories to rank the 
strength of evidence: 
 High = We are very confident that the true effect lies close to that of 
the estimate of the effective 
 Moderate = We are moderately confident in the effect estimate: the 
true effect is likely to be close to the estimate of the effect, but there 
is a possibility that it is substantially different 
 Low = Our confidence in the effect estimate is limited: the true effect 
may be substantially different from the estimate of the effective 
 Very low = Evidence either is unavailable or does not permit  
a conclusions 
The ranking according to the GRADE scheme for the research question can 
be found in Table 4-1. 
Overall, the strength of evidence for the efficacy of natalizumab in compari-
son to an alternative therapy with fingolimod is very low in the outcomes of 
ARR and disability progression. Regarding QoL and number of serious ad-
verse events, no evidence was found.  
However, natalizumab therapy seems to be effective and safe in terms of ARR, 
disability progression and number of serious adverse events, if compared to 
a placebo control. No significant difference was found regarding QoL. Yet, the 
strength of evidence supporting the data is low.  
RCT: niedriges RoB, 
nicht randomisierte 
Kontrollstudien:  
hohes RoB 
nicht kontrollierte 
Studien: mittleres bis 
hohes RoB 
Bewertung der Stärke 
der Evidenz mittels 
GRADE  
Stärke der Evidenz 
niedrig bis sehr niedrig 
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Table 4-1: Summary of findings table 
Outcomes Absolute effects Relative effects 
№ of participants  
(studies) 
Certainty of  
the evidence 
(GRADE) Comments 
Annualized relapse 
rate (ARR) 
Natalizumab: 0.30 vs Fingolimod: 0.31 (p=0.53) Rate ratioa: 0.93 (95%CI: 0.74-1.17) 1,058  
(2 observational trials) 
⨁◯◯◯ 
VERY LOWc 
- 
Natalizumab: 0.24 vs control groupb: 0.73 (p=0.004) 
Natalizumab: 0.53 vs placebo: 1.73 (p=0.001) 
Odds ratio: 0.33 (95% CI: 0.15-0.70) 
- 
94 (1 RCT) ⨁⨁◯◯ 
LOWd,e  
Disability progression 
(assessed with EDSSf) 
- 
 
 
 
Natalizumab: +0.05 vs control groupb: +0.38 (p=0.004) 
Natalizumab (40.1% improved, 31.0% 
unchanged, 28.9% worsened) vs 
Fingolimod (39.9% improved, 32.5% 
unchanged, 27.6% worsened) (p=0.53) 
- 
1,058  
(2 observational trials) 
⨁◯◯◯ 
VERY LOWc 
- 
Natalizumab: -0.22 vs placebo: 0.19 (p=0.019) - 94 (1 RCT) ⨁⨁◯◯ 
LOWd,e 
Analysis not 
prespecified 
Quality of life 
(assessed with VASg) 
Natalizumab: -4.8 points vs placebo: -2.9 points 
(p=0.942) 
- 94 
(1 RCT) 
⨁⨁◯◯ 
LOWd,e 
- 
Number of serious 
adverse events 
Natalizumab: 7/47 (15%) vs placebo: 11/47 (23%) - 94 
(1 RCT) 
⨁⨁◯◯ 
LOWd,e 
Including 
MS relapses 
Natalizumab: 2 (4.6%) vs. control groupb: 1 (1.2%) - 124  
(1 observational trial) 
⨁◯◯◯ 
VERY LOWc  
Natalizumab: 636/5915 (10.75%) - 5,915  
(2 observational trials) 
⨁⨁◯◯ 
LOW  
Abbreviations: RCT = Randomised controlled trial, EDSS= Expanded disability status score, VAS = Visual Analogue Scale 
Explanations: a) adjusted for all covariates b) Natalizumab interrupters c) serious risk of bias due to selection of the participants and selective outcome reporting d) small sample size  
e) short follow-up period f) EDSS scale ranges 0 (normal) to 10 (death) in 0.5 point increments g) VAS ranging from 0 (poor) to 100 (excellent) 
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5 Discussion 
This report evaluated the efficacy and safety of natalizumab therapy in RRMS 
patients seven years after the publication of the first systematic review. In the 
investigated publication period between 2011 and 2018, three studies were 
identified which compared natalizumab with alternative therapies or placebo. 
Concerning clinical effectiveness, evidence was available from three studies 
[27-29]. One RCT with 94 patients (IG=47) and two non-randomised con-
trolled trials with 130 (IG=43) and 1,379 patients (IG=520), respectively, 
were included. A single study provided a direct comparison of natalizumab 
with an alternative therapy suggesting that natalizumab is equally effective as 
the treatment with fingolimod in regard of the annualized relapse rate (REF). 
Both drugs were able to reduce the ARR to 0.30 (95% CI 0.26-0.34) and 0.31 
(95% CI 0.27-0.34), respectively. Similarly, no significant differences in terms 
of disease progression between the two treatments were reported. A similar 
percentage of each group improved (IG: 40.1% vs. CG: 39.9%) remained un-
changed (IG: 31.0% vs. CG: 32.5%) or worsened (IG: 28.9% vs. CG: 27.6%). 
In contrast, the comparison of natalizumab-treated patients with either those 
interrupting natalizumab treatment [28] or a group receiving a placebo con-
trol [27], suggested a benefit of the intervention in both studies (estimated 
RR=0.33 and RR=0.31, respectively). Regarding disability progression, sig-
nificant changes in the EDSS scores between intervention and control groups 
were observed in both trials. However, neither of the variations represented 
a clinically meaningful change, which is considered as a difference between 
1.0 or more if the EDSS at baseline was 0 to 5.5, or 0.5 or more for higher 
baseline EDSS scores [22]. 
In terms of patient-reported quality of life, no evidence was available on 
whether natalizumab is superior to other treatment alternatives. QoL data 
form the RCT comparing natalizumab with a placebo control [27] revealed no 
significant difference between intervention and control groups (p=0.942), 
which could be explained by the small sample size and the short duration of 
the follow-up period. In contrast, data from the AFFIRM and SENTINEL 
trials showed an improved QoL of natalizumab treated patients compared to 
those receiving either placebo or interferon-beta, respectively, after 24 months 
of therapy [35]. 
Concerning safety, three controlled and additional four prospective single-
arm studies with in total 6,872 patients on natalizumab therapy were analysed. 
No evidence was found whether natalizumab therapy is safer than the alter-
native treatment with fingolimod. Yet, if compared to placebo, a reduction 
in the amount of serious adverse events was observed in the intervention 
group (15% versus 23%). However, if MS relapses were excluded from the 
analysis, the proportion of patients suffering from SAEs was higher in the 
natalizumab-treated group than in the placebo control group (6% versus 2%) 
[27]. In the single-arm studies, the percentage of serious adverse events in 
patients who received natalizmab ranged from 2.3% to 16%.  
The reporting of AEs was generally incomplete. Only three studies reported 
the number of adverse events, which ranged from 2.2% [30] to 72% [27] in 
natalizumab treated patients. 
 
klinische Wirksamkeit:  
1 RCT,  
2 nicht-randomisierte 
kontrollierte Studien 
1 Studie dokumentierte 
QoL: kein signifikanter 
Unterschied im 
Vergleich mit Plazebo 
(niedrige Stärke der 
Evidenz) 
Sicherheit: keine 
verfügbare Evidenz  
im Vergleich mit 
alternativen Therapien; 
 
jedoch Daten von  
nicht-kontrollierten 
Studien vorhanden 
unvollständige 
Dokumentation von 
Nebenwirkungen 
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Overall completeness and applicability of evidence 
Concerning the effectiveness of natalizumab in comparison to alternative 
therapies, the quality of evidence was low to very low. The main reasons were 
a lack of RCTs and a serious risk of bias due to selection of participants, 
missing data and indication of selective outcome reporting.  
In particular, only one trial comparing natalizumab with an alternative dis-
ease modifying therapy met the inclusion criteria. In contrast to the conclu-
sion of the study that both treatments are equally effective, other publications 
observed a difference between the two treatments in favour of natalizumab 
[19, 36]. Similarly, a recent network meta-analysis comparing the effective-
ness of available MS drugs ranked natalizumab (RR 0.56; 95% CI 0.47 to 
0.66) as third and fingolimod (RR 0.72; 95% CI 0.64 to 0.81) as fourth most 
effective drugs in preventing the recurrence of relapses in RRMS patients 
after 24 months of treatment [19]. Furthermore, data from a retrospective 
non-randomized controlled trial revealed a higher percentage of relapse-free 
patients (80% vs 66%, p=0.015) as well as a higher percentage of disability-
improved patients (15% vs 6%, p=0.033) in the natalizumab treated group 
than in the fingolimod treated group. Additionally, natalizumab therapy was 
associated with a reduction in MRI-activity (14% vs 38%, p=0.001) and a 
higher percentage of patients with no evidence of disease activity (70% vs 
44%, p<0.001), suggesting that natalizumab is superior to fingolimod in 
patients non-responding to first-line agents [37]. In addition, the analysis 
from the Austrian MS Treatment Registry showed a statistically significant 
difference in the mean annualized relapse rates during a 24 months observa-
tion period, revealing a greater reduction in the natalizumab treated group 
(ARR 0.12 vs. 0.19, p=0.005). Yet, no significant differences were observed 
between the two groups regarding the probability of experiencing a relapse, 
EDSS progression or EDSS regression [36]. 
Two studies were investigating the efficacy of natalizumab compared with 
either those who interrupt the treatment or with a placebo control. The evi-
dence from the RCT comparing patients receiving natalizumab therapy with 
a placebo control group was considered as being low due to the small sample 
size and the short follow-up time. The non-randomized trial was attributed 
with a very low level of evidence due to its high RoB. Both studies showed a 
benefit of natalizumab therapy in line with the literature [8]. 
A single study measured the patient-reported outcome quality of life. Howev-
er, the intervention group was compared to a placebo control. Hence, no evi-
dence/information about differences in QoL of natalizumab treated patients 
compared to patients receiving alternative therapies could be found. Moreo-
ver, the measurement tool (visual analogue scale) was not further specified in 
terms of validity or clinical relevant differences. Therefore, the results could 
not be related to other general HRQoL instruments or any of the MS-specific 
HRQoL questionnaires [38]. 
Generally, the reporting of SAEs and AEs was a point of major concern as 
partial reporting was assumed in several trials. Furthermore, lack of clarity 
regarding the classification of the intervention groups and potential devia-
tion from the intended interventions prevented a comprehensive analysis. 
More accurate information will be available after the publication of the sys-
tematic review of Tramacere and colleagues comparing the adverse effects of 
immunotherapies for people with MS or CIS [39] and the final analyses of 
two ongoing observational studies [30, 31].  
Gründe für die 
Abwertung: fehlen von 
RCTs, hohes RoB, kleine 
Stichprobe, kurzer 
Beobachtungszeitraum 
QoL: Messinstrument 
nicht weiter spezifiziert 
unvollständige 
Dokumentation  
von (schweren) 
Nebenwirkungen 
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In the present analysis, 35 cases of PML cases occurred among 6,872 natali-
zumab treated patients, which gives an estimated incidence risk of 0.5 cases 
per 1,000 patients. Until 2018, more than 700 cases have been reported glob-
ally among natalizumab treated patients [17, 40]. Based on the ongoing re-
porting and research in that area, the manufacturing company has provide 
risk tables for PML that are based on three major known risk factors: more 
than 2 years of natalizumab treatment, JCV seropositivity and prior use of 
immunosuppressants. If all criteria are satisfied in one patient, the risk of 
PML is 11.1 per 1,000 compared to a risk of 0.09 cases per 1,000 in JCV neg-
ative patients [41].  
In general, challenges with interpreting the data arise due to differences in 
outcome reporting and the heterogeneity of the study populations. Further-
more, imprecision due to small sample sizes prevented a quantitative analy-
sis of the data. 
Overall, the data is considered generalizable to other contexts. The studies 
were conducted in Italy, Denmark, Japan, USA and in multinational settings. 
At the same time, however, differences between inclusion and exclusion cri-
teria prevent the generalizability. For instance, the data were recorded in 
hospital setting (clinical trials) or by practising neurologists and physicians. 
In general, the disease status is different between patients enrolled in clini-
cal trials compared to patients treated in clinical practice, which in general 
have a more severe disease [42]. Furthermore, pregnant women, children, or 
patients with other forms of MS were excluded. 
 
Upcoming evidence 
Currently, there are several ongoing randomised controlled trials and obser-
vational studies listed in Clinicaltrials.gov. Among these, there are three head-
to-head trials: BEST-MS is comparing the efficacy of natalizumab versus 
fingolimod in 600 patients with a primary completion date of October 2017 
(NCT01981161), COMBAT-MS is comparing rituximab versus all other fre-
quently used immunomodulating drugs including natalizumab in 3,700 pa-
tients with a primary completion date of June 2021 (NCT03193866) and 
TREAT-MS, which compares traditional versus early aggressive therapy in 
900 patients with a primary completion date of October 2022 (NCT03500328). 
Moreover, data from the ongoing Tysabri observational program (TOP), which 
aims to include 6000 patients with a primary completion date of December 
2028 (NCT00493298), and ongoing national registries with an estimated total 
of 34,000 patients and an estimated primary completion date of December 
2023 will provide extensive material regarding the safety of natalizumab ther-
apy in a clinical practice setting. 
 
Limitations 
The present work was implemented as a systematic review of the literature 
which had been published from 2011 (the publication of the Cochrane Re-
view, ref) onwards. It was not intended to provide an update of the previous 
work of Pucci and colleagues [8], which was simply not possible due to re-
strictions in time, length and resources. Yet, at the same time, this focus rep-
resents a major limitation of this review.  
35 Fälle von PML in 
6.872 Natalizumab 
behandelten 
PatientInnen 
(Inzidenzrate von  
0.5 per 1.000 ) 
Heterogenität der 
Studienpopulationen 
verhindert Meta-analyse 
3 laufende direkte 
Vergleichsstudien, 
multinationale 
Beobachtungsstudien 
sowie nationale Register 
Limitationen: 
Verfassung durch 
einzelne Autorin; 
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Further constraints were applied to eligible studies depending on the respec-
tive trial design. Although the length of the follow-up period of RCTs was not 
restricted, a minimum treatment period of 36 months was applied to meth-
odologically lower quality studies (like non-randomised controlled studies 
and single-arm studies) in order to be able to detect possible long-term as 
well as rare events of natalizumab therapy. Thus, numerous publications an-
alysing shorter treatment periods had to be omited from the analysis. Addi-
tionally, drug trials with shorter follow-up periods or retrospective designs 
were excluded. Finally, only published studies were included. No data from 
posters or abstracts or any other forms of grey literature were used. 
Due to the specific requirements of this report (which was planned and con-
ducted as a Master thesis), only one researcher performed the literature 
search, the selection of eligible publications and the data-extraction in addi-
tion to assessing the risk of bias and evaluating the quality of evidence for 
each outcome. Hence, standard quality assurance processes (e.g. selection of 
studies by two reviewers independently) could not be applied. Additionally, 
the short time period did not allow further requests of clarification from the 
authors of the included publications. 
 
36 Monate 
Beobachtungszeitraum 
für nicht randomisierte 
Studien 
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6 Conclusion 
Considering publications from 2011 onwards, this review aimed to evaluate 
whether natalizumab is superior to alternative therapies in the treatment of 
patients with RRMS over a prolonged treatment period. In case of absence of 
an alternative treatment, a placebo control was considered. Overall, the qual-
ity of evidence was low to very low. No significant differences were observed 
in the single non-randomized controlled study that compared natalizumab 
with the alternative therapy fingolimod in terms of ARR and disability pro-
gression. In terms of safety, no evidence was available whether natalizumab 
was safer than the investigated treatment alternative. 
Thus, future research should aim to provide more accurate data on (serious) 
adverse events. Furthermore, a prolonged observation period for investigat-
ing the efficacy and safety of treatments for patients with chronic diseases 
should be considered. In addition, future studies should aim to apply MRI 
criteria for monitoring disease activity and the success of the therapy and to 
assess health-related quality-of-life using MS-specific questionnaires. Final-
ly, more head-to-head RCTs are required to directly compare the impact of 
treatment alternatives in terms of superiority.  
 
 
keine signifikanten 
Unterschiede zwischen 
Natalizumab und 
Fingolimod in der 
jährlichen Schubrate 
und der 
Krankheitsprogression 
mehr RCTs, welche 
alternative Therapien 
direkt vergleichen, 
sowie umfassendere 
Dokumentation von 
Nebenwirkungen nötig 
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8 Appendices 
8.1 Evidence tables of individual studies included 
for clinical effectiveness and safety 
Table 8.1-1: Evidence table – RCT 
 Saida et al. (2017)[27] 
Country Japan 
Sponsor Biogen 
Study design multi-center, double-blind, placebo-controlled, randomized trial 
Conducted in April 2010 – August 2012 
Indication Japanese patients with RRMS 
Intervention (I) natalizumab, 300mg, IV, every 4 weeks 
Comparator C) placebo 
Number of patients 47 vs. 47 
Inclusion criteria patients aged 18-65 years, diagnosed with RRMS (revised McDonald 
criteria), at least one clinical MS exacerbation within previous year 
and a EDSS score of 0.0-5.5 
Exclusion criteria all other neurological diagnoses (primary or secondary progressive 
MS, neuromyelitis optica (NMSO), and NMO spectrum disorder or 
patients with a history of a long spinal cord lesion extending over 
three or more vertebral bodies or a positive test for AQP4 antibodies 
or prior treatment with natalizumab or immunosuppressants or 
treatment with immunomodulatory drugs within 2 weeks of 
enrolment or during study; corticosteroids were not permitted 
within 30 days of enrolment or except for short courses for 
treatment of relapses during study 
Primary outcome measure rate of development of new active lesions over 24 weeks 
Secondary outcomes measure clinical relapses, EDSS scores, assessment of well-being (VAS)  
and safety 
Baseline patient characteristics (I vs. C) 
Mean age, years (SD) 37.7 (8.6) vs. 35.1 (8.2) 
Female, n (%) 34 (72) vs. 32 (68) 
Mean time since MS diagnosis, years (SD) 5.9 (5.0) vs. 5.1 (4.9) 
Prior MS therapy, n (%) 43 (91) vs. 40 (85) 
Mean number of relapses in previous year (SD) 2.0 (1.2) vs. 1.9 (1.0) 
Mean number of EDSS score (SD) 2.5 (1.6) vs. 2.1 (1.5) 
Follow-up time, months 6 
Loss to follow-up, n (%) 5 (5.3) 
Efficacy 
Annualized relapse rate, ARR  
(Difference between I and C) 
0.53 vs. 1.73 with p=0.001 
Disability progression  
(Difference between I and C) 
- 0.22 (0.7) vs. 0.19 (0.9) with p=0.019 
QoL (VAS) - 4.8 points vs. '- 2.9 points with p=0.942 
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 Saida et al. (2017)[27] 
Safety 
number of serious adverse eventsa (%) 7 (15) vs. 11 (23) 
infections and infestations 0 vs. 1 (2) 
neoplasms 1 (2) vs. 0 
PML 0 vs. 0 
number of adverse eventsb (%) 34 (72) vs. 41 (87) 
hypersensitivity reaction 0 vs. 0 
anti-JCV antibodies 65 (63) of 103 patientsc 
anti-natalizumab antibodies 1 (2) vs. 0 
Explanations: a) including MS relapses, b) at least one adverse event (including MS relapses),  
c) participants from the extension study which included patients from the RCT plus patients from the pharmacokinetic study  
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Table 8.1-2: Evidence table – non-randomised controlled trials 
 Clerico et al. (2014)[28] Koch-Hensiksen et al. (2016)[29] 
Country Italy Denmark 
Sponsor NA NA 
Study design non-randomized, prospective, controlled multicenter study non-randomized, prospective, controlled multicenter study 
Conducted in October 2010 – October 2013 July 2011 – October 2015 
Indication evaluating MS clinical activity in patients with RRMS after 
24 doses of natalizumab 
to compare the clinical efficacy of natalizumab and fingolimod 
Intervention (I) natalizumab, 300mg, IV, every 4 weeks natalizumab 
Comparator C) no treatment or DMT (interferon beta, glatiramer acetate, 
fingolimod) or mitoxantrone hydrochrloride 
fingolimod 
Number of patients 130 1379 
Inclusion criteria 18 years or older with clinically definite RRMS who 
received 24 doses of Natalizumab, with clinical and MR 
imaging MS stability, and which had at least 1 MR image 
within 10 days after 24 doses of natalizumab 
All patients, who started treatment with natalizumab or fingolimod from 
1 July 2011 up to 31 March 2015. RRMS patients should under first-line 
treatment with interferon-beta or glatiramer acetate have had at least 
one significant relapse within one year. Hitherto treatment-naive patients 
could start second-line treatment directly if they within a year have had 
two serious relapses with residual symptoms and an active magnetic 
resonance imaging (MRI) scan with gadolinium positive lesion(s) or a 
significant increase in T2 lesions compared with earlier MRI scans. 
Exclusion criteria pregnancy, severe depression, alcohol or drug addition, 
any clinical condition in addition to MS 
NA 
Primary outcome measure mean ARR annualized relapse rate (ARR) 
Secondary outcomes measure MR imaging MS activity and mean EDSS rates of steroid-treated relapse, proportion of patients remaining free  
of relapse, time to first relapse, proportion of patients in whom EDSS 
improved or worsened during treatment 
Baseline patient characteristics (I vs. C) 
Mean age, years (SD) 37.4 (9.5) vs. 39.5 (9.8) 38.7 (10.1) vs. 39.3 (10.1) 
Female, n (%) 32 (74.4) vs. 56 (69.1) (70.5) vs. (70.5) 
Mean time since MS diagnosis, years (SD) 9.96 (5.85) vs. 12.19 (7.32) 7.78 (6.2) vs. 7.69 (6.3) 
Prior MS therapy, n (%) 35 (81.4) vs. 73 (90.1) 437 (94.2) vs. 437 (94.2) 
Mean number of relapses in previous year (SD) 2.29 (1.53) vs. 1.84 (1.17) 1.06 (0.95) vs. 1.05 (1.1) 
Mean EDSS score (SD) 3.31 (1.65) vs. 3.42 (1.73) 3.15 (1.6) vs. 3.08 (1.5) 
Follow-up time, months 12 51 
Loss to follow-up, n (%) 6 (4.6) 70 (5.1) 
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 Clerico et al. (2014)[28] Koch-Hensiksen et al. (2016)[29] 
Effectiveness 
Annualized relapse rate, ARR  
(Difference between I and C) 
0.24 (0.48) Nat. continuers vs. 0.73 (0.85) Nat. 
interrupters with p=0.004 
0.296 (95%CI: 0.26-0.34) vs. 0.307 (95%CI: 0.27-0.35);  
rate ratio of 0.93 (95%CI: 0.74-1.17) with p=0.53 
Disability progression  
(Difference between I and C) 
3.36 (1.69) vs. 3.80 (1.83) with p=0.23 186 (40.1%) improved, 144 (31.0% remained unchanged and 134 (28.9%) 
worsened vs. 185 (39.9%) improved, 152 (32.5%) remained unchanged, 
128 (27.6%) worsened (p=0.86) 
QoL NA NA 
Safety 
number of serious adverse events (%) 3 (2.3) NA 
infections and infestations 1 (0.8) NA 
neoplasms NA NA 
PML 1 (0.8) NA 
number of adverse events (%) NA NA 
hypersensitivity reaction NA NA 
anti-JCV antibodies NA NA 
anti-natalizumab antibodies NA NA 
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Table 8.1-3: Evidence table – single-arm studies 
 Butzkueven et al. (2014)[30] O'Connor et al. (2014)[31] Totaro et al. (2014)[32] Zivadinov et al. (2016)[33] 
Country multinational multinational Italy USA 
Sponsor Biogen Biogen (editorial support) NA Biogen 
Study design prospective, observational 
study, single-arm (Tysabri 
Observational Program-TOP) 
prospective, observational,  
single-arm study (Safety of Tysabri 
re-dosing and treatment (STRATA) 
prospective, observational,  
single-arm study 
prospective, observational,  
single-arm study 
Conducted in July 2007 – December 2012a – February 2012i April 2007 – November 2010 NA 
Indication evaluate long-term safety of 
natalizumab monotherapy 
evaluate safety of  
natalizumab monotherapy 
evaluate efficacy and tolerability of 
natalizumab in a cohort of RRMS 
patients 
re-evaluation of natalizumab-
treated relapsing MS patients 
Intervention (I) natalizumab, 300mg, IV,  
every 4 weeks 
natalizumab, 300mg, IV,  
every 4 weeks 
natalizumab natalizumab, 300mg, IV,  
every 4 weeks 
Comparator (C) NONE NONE NONE NONE 
Number of patients 4821 1094 343 77 
Inclusion criteria Patients with RRMS who met 
criteria for natalizumab 
prescription in their respective 
countries and had three or 
fewer natalizumab infusions 
before enrolment. Female 
participants were postmeno-
pausal, surgically sterile, or 
willing to practice effective 
contraception. 
patients with RRMS previously 
participating in a natalizumab 
“feeder” study (AFFIRM, SENTINEL, 
GLANCE, STARS) 
RRMS according to the McDonald 
criteria; criterion A, patients on pre-
vious immunomodulation treatment 
for at least 12 months who had 
experienced either two relapses in 
the last year or a single relapse with 
incomplete recovery and residual 
disability, with at least 9 T2 lesions, 
or an increased lesion burden or at 
least 1 gadolinium-enhanced lesion; 
criterion B, patients with severe MS 
with a fast evolution, even if not 
previously treated with immuno-
modulation treatments, with 2 or 
more relapses with increased 
disability during the previous year, 
and with new T2- or gadolinium-
enhanced lesions on MRI, compared 
with an MRI examination performed 
during the previous 12 months. 
participation in the natalizumab 
VWMTR study, age 18-65; 
diagnosis of MS according to the 
McDonald 2005 criteria of either 
RR or relapsing secondary-
progressive disease type,  
EDSS score ≤ 6.5;  
disease duration < 30 years, 
received > 1 cycle of natalizumab 
and fulfilled the TOUCH 
enrolment requirements 
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 Butzkueven et al. (2014)[30] O'Connor et al. (2014)[31] Totaro et al. (2014)[32] Zivadinov et al. (2016)[33] 
Exclusion criteria NA concomitant immunosuppressive or 
immunomodulatory treatment; 
persistently positive anti-natalizumab 
antibodies, compromised immune 
system; prior natalizumab 
discontinuation because of related 
allergic reaction or serious adverse 
event; malignancy history, or any 
major disease precluding 
recombinant humanized 
immunomodulatory antibody use. 
NA presence of relapse and steroid 
treatment in the 30 days preceding 
the 5-year MRI scan, pre-existing 
medical conditions known to be 
associated with brain pathology 
(cerebrovascular disease, positive 
history of alcohol abuse) and 
pregnancy. 
Primary outcome measure long-term safety (incidence and 
type of serious adverse events) 
safety after re-exposure to 
natalizumab 
proportion of patients who were free 
from relapses/EDSS progression/ 
combined clinical activity/MRI 
activity/any disease activity 
determine the association between 
the number of natalizumab cycles 
and brain volume loss, lesion 
burden, disability progression  
and relapse rate 
Secondary outcomes measure occurrence of clinical relapses, 
change in EDSS score 
frequency of relapses, change in 
EDSS score 
annualized clinical relapse rate determine MRI and clinical changes 
between those patients who 
received natalizumab for 5 years 
and those patients who received 
natalizumab treatment with some 
periods of honeymoon and those 
who discontinued treatment 
Baseline patient characteristics 
Mean age, years (SD) 37.2 (9.69) 41.1 (8.1) 35.8 (9.1) 41.3 (10)b (n=60) 
Female, n (%) 3466 (72) (69) 247 (72) 42 (70)b (n=60) 
Mean time since MS 
diagnosis, years (SD) 
7.3 (0-43.9)b (n=4799) 8 (4-34)b (n=1088) 10.7 (6.8) 12.7 (8.0)b (n=60) 
Prior MS therapy, n (%) 4384 (90.9) (94.8) 330 (96.2) 77 (100) 
Mean number of relapses  
in previous year (SD) 
1.99 (1.03) 1 (0-8)b at least one relapse in 341 patients NA 
Mean EDSS score (SD) 3.5 (1.62)(n=4728) 2.5 (0-8)b 2.8 (1.5) 3.0 (0-7)b (n=60) 
Follow-up time, months 60c 60 42 60 
Loss to follow-up, n (%) 121 (2.5)d 462j 57 (16.6)n 17 (22) 
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 Butzkueven et al. (2014)[30] O'Connor et al. (2014)[31] Totaro et al. (2014)[32] Zivadinov et al. (2016)[33] 
Effectiveness 
Annualized relapse rate, ARR 12 months: 0.30 (n=4821);  
24 months: 0.24 (n=3433);  
36 months: 0.24 (n=2224);  
48 months: 0.21 (n=1000);  
60 months: 0.24 (n=355) 
12 months: 0.21 (n=632);  
24 months: 0.14 (n=6323);  
36 months: 0.15 (n=632);  
48 months: 0.10 (n=632);  
60 months: 0.11 (n=632) 
12 months: 0.19 (0.5) (n=203);  
24 months: 0.11 (0.5) (n=102);  
36 months: 0.13 (0.4) (n=30) 
1.5 (1.9)b 
Disability progression 12 months: 3.3 (1.76) (n=2064); 
24 months: 3.34 (1.84)(n=1304); 
36 months: 3.3 (1.84) (n=744); 
48 months: 3.3 (1.92) (n=325) 
12 months: 2.72 (n=616);  
24 months: 2.75 (n=594);  
36 months: 2.87 (n=588);  
48 months: 2.91 (n=571);  
60 months: 2.91 (n=561) 
12 months: 3.1 (1.5)(n=218);  
24 months: 3.0 (1.5) (n=112);  
36 months: 2.9 (1.4) (n=36) 
3.0 (0-7)b 
QoL NA NA NA NA 
Safety 
number of serious adverse 
events (%) 
465e or 388 (8.0)f,g 171 (16)k NA NA 
infections and infestations 97 or 93 (1.9) 44 (4) NA NA 
neoplasms 24 or 24 (0.5) 25 (2) NA NA 
PML 18 or 18 (0.4) 14l 0 2 (2.5) 
number of adverse events (%) 107 (2.2) NA 116 (33.8) NA 
hypersensitivity reaction NA 55 (5)b,m NA NA 
anti-JCV antibodies (%) 277 (5.7) (67) NA NA 
anti-natalizumab antibodies 44 (0.9)h NA NA NA 
Explanations: a) scheduled follow-up period: 120 months; b) Median; c) Median follow-up of 26 months; d) loss-to follow-up was considered as one reason given by patients who withdrew from TOP 
(n=740 (15.3%)); e) all SAEs occurred during natalizumab therapy or within 6 months after natalizumab discontinuation; f) for incidence calculation, a patient is counted once per lower-level term 
(LTT); g) including 9 deaths; h) not routinely collected; i) variable starting point of the feeder-studies; j) 217 completed initial STRATA period, but did not enter extension study; 245 discontinued study; 
k) patients with at least one serious adverse event; l) until August 23, 2013; m) during first 48 weeks; n) treatment was stopped 
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8.2 Risk of bias tables 
Table 8.2-1: Risk of bias table – RCT 
Study Bias arising from the 
randomization process 
Bias due to deviations from 
intended interventions 
Bias due to missing 
outcome data 
Bias in measurement  
of the outcome 
Bias in selection  
of the reported result 
Overall bias 
Saida et al. (2017)[27] Low Low Low Low Low Low 
 
Table 8.2-2: Risk of bias table – non-randomised controlled trials 
Study Clerico et al. (2014)[28] Koch-Henriksen et al. (2016)[29] 
Domain 1: Confounding Moderate Moderate 
Domain 2: Selection Serious Moderate 
Domain 3: Classification of intervention Serious Low 
Domain 4: deviation from intervention Moderate/Serious Moderate 
Domain5: missing data Low Serious 
Domain 6: measurement of outcomes Low no information 
Domain 7: selection of reported result Moderate Serious 
Overall risk of Bias Serious Serious 
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Table 8.2-3: Risk of bias – single-arm studies 
Study reference/ID Butzkueven et al. 
(2014)[30] 
O'Connor et al. 
(2014)[31] 
Totaro et al. 
(2014)[32] 
Zivadinov et al. 
(2016)[33] 
Study objective 
1. Was the hypothesis/aim/objective of the study clearly stated? Yes Yes Yes Yes 
Study design 
2. Was the study conducted prospectively? Yes Yes Unclear Yes 
3. Were the cases collected in more than one centre? Yes Yes Yes Nof 
4. Were patients recruited consecutively? Unclearb Unclearb Yes Unclear 
Study population 
5. Were the characteristics of the participants included in the study described? Yes Yes Yes Yes 
6. Were the eligibility criteria (inclusion and exclusion criteria) for entry into the study clearly stated? Partial Yes Partial Yes 
7. Did participants enter the study at similar point in the disease? Yes Unclear Unclear Nog 
Intervention and co-intervention 
8. Was the intervention clearly described? Yes Yesc No Yes 
9. Were additional interventions (co-interventions) clearly described? No Yesd No Partial 
Outcome measure 
10. Were relevant outcome measures established a priori? Yes Yes Yes Yes 
11. Were outcome assessors blinded to the intervention that patients received? Unclear Unclear Unclear Unclear 
12. Were the relevant outcomes measured using appropriate objective/subjective methods? Yes Yes Yes Yes 
13. Were the relevant outcomes measured before and after interventions? Yes Yes Yes Yes 
Statistical Analysis 
14. Were the statistical tests used to assess the relevant outcome appropriate? Yes Unclear Yes Yes 
Results and conclusions 
15. Was follow-up long enough for important events and outcomes to occur? Yes Yes Yes Yes 
16. Was the loss to follow-up reported? Yes Yes No Yes 
17. Did the study provide estimates of random variability in the data analysis of relevant outcomes? Yes Partiale Yes Yes 
18. Were adverse events reported? Yes Yes Partial Partial 
19. Were the conclusions of the study supported by the results? Yes Yes Yes Yes 
Competing interests and source of support 
20. Were both competing interest and source of support for the study reported? Yes Yes Partial Yes 
Overall Risk of Bias Moderate Moderate High Moderate 
Explanations: a) uncontrolled longitudinal study/case series according to the Cochrane Handbook Box 13.1a; b) multinational study;  
c) in the abstract; d) Patients were required to discontinue concomitant immunosuppressive or immunomodulatory treatment for the study’s duration;  
e) Estimates of random variability were only reported once; f) information provided in VWMTR study abstract; g) EDSS range (0-7) 
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8.3 GRADE Evidence profile tables 
Table 8.3-1: Grade evidence table 
Certainty assessment 
Impact Certainty Importance № of studies 
(participants) 
Study design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Annualized relapse rate 
1 (94) RCT not 
serious 
not serious not serious very seriousa,b  
(-2) 
none Natalizumab: 0.53 vs placebo: 1.73 (p=0.001) ⨁⨁◯◯ 
LOW 
CRITICAL 
2 (1058) observational 
trials 
seriousc 
(-1) 
not serious not serious not serious none Natalizumab: 0.30 vs fingolimod: 0.31 (p=0.53) 
Natalizumab: 0.24 vs control groupd: 0.73 (p=0.004) 
⨁◯◯◯ 
VERY LOW  
Disability progression (assessed with: EDSS) 
1 (94) RCT not 
serious 
not serious not serious very seriousa,b  
(-2) 
none Natalizumab: -0.22 vs placebo: 0.19 (p=0.019) ⨁⨁◯◯ 
LOW 
CRITICAL 
2 (1058) observational 
trials 
seriousc 
(-1) 
not serious not serious not serious none Natalizumab: +0.05 vs control groupd: -0.38 (p=0.004) 
Natalizumab (40.1% improved, 31.0% unchanged, 
28.9% worsened) vs Fingolimod (39.9% improved, 
32.5% unchanged, 27.6% worsened) (p=0.53) 
⨁◯◯◯ 
VERY LOW  
Quality of Life (assessed with: VAS) 
1 (94) RCT not 
serious 
not serious seriouse (-1) seriousa (-1) none Natalizumab: -4.8 points vs placebo: -2.9 points 
(p=0.942) 
⨁⨁◯◯ 
LOW 
IMPORTANT 
Number of Serious adverse events 
1 (94) RCT not 
serious 
not serious not serious very seriousa,b none Natalizumad: 7/47 (15%)f vs placebo: 11/47 (23%)f ⨁⨁◯◯ 
LOW 
CRITICAL 
1 (130) observational 
trials 
seriousg 
(-1) 
not serious not serious not serious none Natalizumab: 2/43 (4.7%) vs. controld: 1/81 (1.2%) ⨁◯◯◯ 
VERY LOW  
2 (5915) observational 
(single arm) 
trials 
not 
serious 
not serious not serious not serious none Natalizumab: 636/5915 (10.75%) ⨁⨁◯◯ 
LOW  
Abbreviations: RCT = Randomised controlled trial, EDSS = Expanded disability status score, VAS = Visual Analogue Scale 
Explanations: a) small sample size; b) short follow-up period; c) selection of the participants; d) natalizumab interrupters; e) appled test not validated; f) including MS relapses; g) missing data 
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect; 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect; 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect 
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8.4 Applicability table 
Table 8.4-1: Summary table characterising the applicability of a body of studies 
Domain Description of applicability of evidence 
Population The population enrolled in the studies is similar to the target population of the intervention. The patients were of similar age and the proportion of women was 
similar. The patients suffered from 1 to 2 relapsles prior to natalizumab treatment and their EDSS score was comparable. However, there were also a number of 
differences between the inclusion and exclusion criteria. The most important one was that some studies included treatment-naïve patients while others included 
patients which had already received the intervention for a certain amount of time.  
Intervention The intervention under assessment is natalizumab. Its product name is Tysabri®. 
Comparators The comparators were either fingolimod (alternative treatment option), placebo or a group of natalizumab treatment interruptors. 
Outcomes The crucial outcomes considered are annualized relapse rate (ARR), disability progression measured by EDSS, quality of life (QoL) and number of serious 
adverse events (SAEs). Further outcomes considered are the number of adverse events. 
Setting All of the studies included were either single-centre or multi-centre studies, with clinical centres based in Europe (Italy and Denmark), USA and Japan.  
These contexts are considered similar to the Austrian one. 
 
 
8.5 List of ongoing randomised controlled trials and observational studies 
Table 8.5-1: List of ongoing randomised controlled trials and observational studies 
Identifier/Trial name 
Patient 
population 
Estimated 
enrolment Intervention Comparison Primary Outcomes 
Primary 
completion date Sponsor 
NCT01981161/Difference in efficacy of 
natalizumab versus fingolimod for the 
treatment of multiple sclerosis BEST-MS 
RRMS 600 Natalizumab Fingolimod disease free patients October  
2017 
University 
Hospital, 
Toulouse 
NCT02588053/Does long-term 
natalizumab therapy normalize brain 
atrophy rates and quality of life (QoL) 
in relapsing remitting multiple sclerosis 
(RRMS)? 
RRMS 146 Natalizumab - change in brain atrophy rate August  
2018 
US NIH Grant 
NCT03516526/Towards personalized 
dosing of natalizumab in multiple 
sclerosis (PDNMS) 
RRMS 60 Natalizumab - gadolinium enhancing  
T1 lesions on brain MRI 
June  
2019 
VU University 
Medical Center 
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Identifier/Trial name 
Patient 
population 
Estimated 
enrolment Intervention Comparison Primary Outcomes 
Primary 
completion date Sponsor 
NCT01485003/Observational study  
of tysabri in early relapsing-remitting 
multiple sclerosis in anti-JC virus 
antibody negative patients ( STRIVE) 
RRMS 231 Natalizumab - Proportion of participants who 
are overall disease activity-
free at months 12 and 24; 
proportion of participants who 
are clinical disease activity-
free at months 36 and 48 
October  
2018 
Biogen 
NCT01065727/Impact study of  
2 therapeutic strategies for aggressive 
remitting multiple sclerosis (IQUALYSEP) 
RRMS 250 mitoxantrone 
followed by 
immunomodulator 
Natalizumab cost effectiveness February  
2016 
Rennes 
University 
Hospital 
NCT00493298/Tysabri observational 
program (TOP) 
RRMS 6000 Natalizumab - Number of participants with 
serious adverse events 
December 
2028 
Biogen 
NCT03399981/Tysabri observational 
cohort study – multiple sclerosis (MS) 
registries 
MS 34600 Natalizumab - prospective and 
retrospective analyses: 
number of participants with 
confirmed PML; number of 
participants with serious 
adverse events of other 
serious opportunistic 
infections 
December 
2023 
Biogen 
NCT03193866/Comparison between all 
immunotherapies for multiple sclerosis 
(COMBAT-MS) 
CIS or 
RRMS 
3700 Rituximab all other frequently used 
immunomodulating 
drugs (natalizumab, 
fingolimod, 
alemtuzumab, 
interferon-beta, 
glatiramer acetate, 
dimethyl fumarate 
confirmed disease 
progression in patients with 
EDSS ≤ 2.5 at baseline; 
confirmed disease 
progression in patietns with 
EDSS ≥ 2.5 at baseline; 
Disease-related impact  
on daily life 
June  
20121 
Karolinska 
Institutet 
NCT03500328 /Traditional versus early 
aggressive therapy for multiple 
sclerosis trial (TREAT-MS) 
RRMS 900 Early aggressive 
Therapy: 
Natalizumab, 
Alemtuzumab, 
Ocrelizumab, 
Rituximab 
traditional therapy: 
Glatiramer acetate, 
intramuscular interferon, 
subcutaneous interferon, 
pegylated interferon, 
teriflunomide, dimethyl 
fumarate, fingolimod 
time to sustained disability 
progression 
October  
2022 
Johns Hopkins 
University 
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8.6 List of excluded studies 
Table 8.6-1: Table of excluded studies  
Author Title Reason for exclusion 
Barbin et al. (2016) [43] Comparative efficacy of fingolimod vs natalizumab: A French multicentre observational study Follow-up ≤ 24 months/retrospective 
Baroncini et al. (2016) [37] Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding  
to first-line injectable therapies 
Follow-up ≤ 24 months 
Berkovich et al. (2015) [44] CD4 cell response to interval therapy with natalizumab Wrong objective 
Disanto et al. (2016) [45] The Swiss Multiple Sclerosis Cohort-Study (SMSC): A prospective Swiss wide investigation of key phases  
in disease evolution and new treatment options 
Follow-up ≤ 24 months 
Fernandez et al. (2012) [46] Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study Follow-up ≤ 24 months/retrospective 
Fox et al. (2014) [47] MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study Follow-up ≤ 24 months 
Giacoppo et al. (2017) [48] The Italian pharmacovigilance program: an observational study of adverse effects of Natalizumab  
in multiple sclerosis therapy 
Retrospective 
Guger et al. (2018) [36] Real-life clinical use of natalizumab and fingolimod in Austria Follow-up ≤ 24 months 
Holmen et al. (2011) [49] A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis Follow-up ≤ 24 months 
Jokubaitis et al. (2016) [50] Predictors of long-term disability accrual in relapse-onset multiple sclerosis Erratum 
Jokubaitis et al. (2013) [51] The Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study  
of drug utilisation using the MSBase platform 
Wrong objective/retrospective 
Kalincik et al. (2015) [52] Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis Follow-up ≤ 24 months 
Kallweit et al. (2012) [53] Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent  
of disease activity and disability at baseline: real-life data from a Swiss cohort 
Retrospective 
Kaufman et al. (2015) [54] Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE Retrospective 
Mancardi et al. (2011) [55] Three years of experience: the Italian registry and safety data update Follow-up ≤ 24 months 
Marrosu et al. (2011) [56] The cohort of the multiple sclerosis center of Cagliari Follow-up ≤ 24 months 
Melin et al. (2012) [57] Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with 
relapsing-remitting multiple sclerosis 
Follow-up ≤ 24 months 
Outteryck et al. (2014) [58] A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients:  
clinical, radiological and biological features and adverse events. The BIONAT cohort. 
Follow-up ≤ 24 months 
Piehl et al. (2011) [59] Swedish natalizumab (Tysabri) multiple sclerosis surveillance study Same study population as Holmen [49] 
Planche et al. (2017) [60] Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with  
multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study 
Wrong objective (outcomes) 
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Author Title Reason for exclusion 
Prosperini et al. (2011) [61] Natalizumab treatment in multiple sclerosis: the experience of S.Andrea MS Centre in Rome Follow-up ≤ 24 months 
Prosperini et al. (2017) [62] Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs  
in non-responders and in treatment-naïve patients with multiple sclerosis 
Follow-up ≤ 24 months, retrospective 
Puz, Lasek-Bal (2016) [63] Safety and Efficacy of fingolimod and natalizumab in multiple sclerosis after the failure of first-line 
therapy: single center experience based on the treatment of fourty-four patients 
Follow-up ≤ 24 months 
Raffel et al. (2017) [64] Inflammatory activity on natalizumab predicts short-term but not long-term disability in mulitple sclerosis Retrospective 
Rinaldi et al. (2012) [65] Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis Wrong objective (outcomes) 
Sangalli et al. (2011) [66] Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients:  
a post-marketing observational study 
Follow-up ≤ 24 months 
Van Pesch et al. (2014) [67] Safety and efficacy of natalizumab in Belgian multiple sclerosis patients:  
subgroup analysis of the natalizumab observational program 
Follow-up ≤ 24 months 
Wiendl et al. (2016) [68] EPOCH analysis of on-treatment disability progression events over time  
in the Tysabri Observational Program (TOP) 
Same study population as Butzkeuven 
[30] 
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8.7 Literature search strategies 
Search strategy for Toxline 
Search date: 16.08.2018 
1# natalizumab relapsing remitting multiple sclerosis 
 singular and plural forms were searched 
 records with: all of the words 
 search restricted to documents published between 2011-2018. 
 languages: English 
Total: 110 hits 
 
Search strategy for Clinicaltrials.gov 
Search date: 16.08.2018 
1# Relapsing-Remitting Multiple Sclerosis 
 other terms: natalizumab 
 eligibility criteria: adult (18-64) 
 phase 3 and 4, with results 
Total: 8 hits 
 
Search strategy for Cochrane Central 
Search date: 16.08.2018 
1# MeSH [Multiple Sclerosis, Relapsing-Remitting] explode all trees (707) 
2# 2 MeSH [Natalizumab] explode all trees (78) 
3# #1 and #2 
4# with publication year from 2011 to 2018; in Trials. 
Total: 21 hits 
 
Search strategy for Medline 
Search date: 15.08.2018 
1# exp Multiple Sclerosis 
2# Multiple Sclerosis.mp 
3# 1 or 2 
4# exp natalizumab 
5# natalizumab.mp 
6# 4 or 5 
7# 3 and 6 
8# limit 7 to (human and English language and embase and (clinical trial or randomized controlled trial or 
controlled trial or multicenter study or phase 3 clinical trial or phase 4 clinical trial) and yr=”2011-Current”  
and adult <18 to 64 years>) 
Total: 139 hits 
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Search strategy for Embase 
Search date: 15.08.2018 
1# exp Multiple sclerosis/ 
2# Multiple Sclerosis.mp 
3# 1 and 2 
4# exp Natalizumab/ 
5# Natalizumab.mp 
6# 4 or 5 
7# 3 and 6 
8# limit 7 to (English language and humans and yr=”2011-Current”and “all adult (19 plus years)”and (clinical study 
or clinical trial, phase iii or clinical trial, phase iv or clinical trial or comparative study or controlled trial or 
multicenter study or randomized controlled trial or observational study) and medline) 
Total: 99 hits 
 
 

  
 
 
 
